The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | The potential benefits of fixed-duration bispecific antibody therapy in multiple myeloma
Ravi Vij, MD, MBA, Washington University School of Medicine, St. Louis, MO, discusses the potential for fixed-duration bispecific antibody therapy to provide durable responses without continuous treatment in relapsed/refractory multiple myeloma. He highlights the potential to reduce infection risk and T-cell exhaustion by limiting treatment exposure, while emphasizing the need for further studies to determine whether these findings extend to other bispecific antibodies and targets.This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
